Modimelanotide (INN; development code AP-214, ABT-719, and ZP-1480) is a melanocortinergic peptide drug derived from ñ-melanocyte-stimulating hormone (ñ-MSH) which was under development by, at different times, Action Pharma, Abbott Laboratories, AbbVie, and Zealand for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist, with IC<sub>50</sub> values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC<sub>1</sub>, MC<sub>3</sub>, MC<sub>4</sub>, and MC<sub>5</sub> receptors. Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models, and development was not further pursued.